Bicycle Therapeutics (BCYC)
NASDAQ: BCYC
· Real-Time Price · USD
7.43
-1.63 (-17.99%)
At close: May 06, 2025, 3:59 PM
7.54
1.41%
After-hours: May 06, 2025, 07:13 PM EDT
-17.99% (1D)
| Bid | 7.3 |
| Market Cap | 514.52M |
| Revenue (ttm) | 25.73M |
| Net Income (ttm) | -203.27M |
| EPS (ttm) | -3.16 |
| PE Ratio (ttm) | -2.35 |
| Forward PE | -2.18 |
| Analyst | Buy |
| Ask | 9.56 |
| Volume | 545,551 |
| Avg. Volume (20D) | 339,005 |
| Open | 9.03 |
| Previous Close | 9.06 |
| Day's Range | 7.40 - 9.08 |
| 52-Week Range | 6.10 - 28.67 |
| Beta | 1.40 |
About BCYC
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial ...
Industry Biotechnology
Sector Healthcare
IPO Date May 23, 2019
Employees 305
Stock Exchange NASDAQ
Ticker Symbol BCYC
Analyst Forecast
According to 11 analyst ratings, the average rating for BCYC stock is "Buy." The 12-month stock price forecast is $24, which is an increase of 222.80% from the latest price.
Stock ForecastsNext Earnings Release
Bicycle Therapeutics is scheduled to release its earnings on May 13, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+13.9%
Bicycle Therapeutics shares are trading higher aft...
Unlock content with
Pro Subscription
7 months ago
-7.59%
Bicycle Therapeutics shares are trading lower. The company announced updated Phase 1/2 clinical results for Bicycle Toxin Conjugate zelenectide pevedotin in metastatic urothelial cancer; BTC molecule BT5528 in advanced solid tumors, such as mUC and ovarian; and Bicycle Tumor-Targeted Immune Cell Agonist BT7480 in advanced solid tumors.
